ER Editor: Ivermectin has been shown to be something of a wonder drug against Covid. Dr. Pierre Kory has been leading the charge on this.
So much so that WHO scientists are conducting serious review of it (see WHO-Sponsored Preliminary Review Indicates IVERMECTIN Effectiveness [VIDEO]).
SO MUCH SO THAT INDIA IS GIVING IVERMECTIN-BASED HOME TREATMENT KITS TO ITS CITIZENS at a mere cost of two bucks each.
Merck has decided to abandon development of its own vaccine (two of them, in fact) for a drug-based approach that is NOT Ivermectin. That is another, more expensive drug (two of them, in fact) from which greater revenues can be derived. See Merck First US Pharma Giant To Abandon COVID Vaccine Efforts. Of note:
The company stated that instead it will focus on research into therapeutic drugs labeled as MK-7110 and MK-4482.
The drugs aim to protect patients from the damage of an overactive immune response to the virus.
“Interim results from a Phase 3 study showed a greater than 50 percent reduction in the risk of death or respiratory failure in patients hospitalized with moderate to severe COVID-19,” the company’s statement noted of the MK-7110 drug.
Merck is to receive around $356 million from the US government to fast-track production of the potential treatments under Operation Warp Speed.
Chief Marketing Officer Michael Nally recently told Bloomberg that Merck is aiming to produce some 20 million courses of the MK-4482 drug, an oral antiviral which patients will take twice a day for five days.
So what is the logical step for Merck to take with respect to its own wonder drug Ivermectin? Why, to trash it, of course, using particular mouthpieces. Here is Merck’s statement on its own cheap and highly effective product, linked to in a tweet below:
Black is white …
Merck Statement Against Ivermectin Exposing ‘Big Pharma’ Lobbyists
SWISS POLICY RESEARCH
All Global Research articles can be read in 27 languages by activating the “Translate Website” drop down menu on the top banner of our home page (Desktop version).
A positive aspect of the recent anti-ivermectin statement by Merck is that dozens of ‘big pharma’ lobbyists who immediately shared the statement on Twitter are now getting exposed, among them many journalists, a US NIH representative, some industry-linked professors, and one of the most influential German government ‘covid science communicators’.
Keep in mind that Merck provided no evidence, whatsoever, for any of its claims, did not refute any of the existing evidence, studies and meta-studies, and falsely claimed ‘unproven safety’. The entire statement is a desperate appeal to (supposed) authority, and anyone pushing it is simply exposing themselves as a lobbyist not interested in actual evidence-based medicine.
What Merck could have done, but didn’t do, since April 2020, is running and publishing its own ivermectin trial. What Merck also could have done, but didn’t do, is disclosing in its statement that it recently signed a $356 million deal to supply the US with a much more expensive, newly developed experimental anti-covid drug.
But doing this may not have been in Merck’s interest, of course.